April 2008 | Nefrología

Advanced Search

Share

Español English

April 2008

Nefrología (English Edition)

ISSN: 2013-2514

Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages. Nefrología follows the publication requirements of the International Committee of Medical Journal Editors (ICMJE) and the Committee on Publication Ethics (COPE).

See more

Indexed in:

MEDLINE, EMBASE, IME , IBECs, Scopus and SCIE/JCR

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

See more

Impact factor 2022

2.6

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2022

1.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2022

0.15

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2022

1.947

View more metrics

Journal Information

Previous Issue | Next Issue

Issue

Vol. 28. Issue. S2.
April 2008

Pages 1-50

The supplements of Evidence-Based Nephrology as a tool for continual medical education.

V. Barrio LucIa, F. García López, C. Quereda Rodríguez-Navarro

Nefrologia (English Version). 2008;28 Supl 2:1

Is the failure rate in remission induction lower with mycophenolate mofetil than with cyclophosphamide in lupus nephritis?

C. Galeano, C. Quereda

Nefrologia (English Version). 2008;28 Supl 2:4-5

Is plasmapheresis more effective than 6-methylprednisolone pulses in the management of patients with vasculitis and severe renal involvement?

A. Segarra

Nefrologia (English Version). 2008;28 Supl 2:6-7

Does the treatment focused on controlling the activity of the underlying inflammatory disease and reducing the serum level of AA protein improve the prognosis of systemic amyloidosis?

V. Barrio, F. Ortiz-Herbener

Nefrologia (English Version). 2008;28 Supl 2:8-9

Is the combination aliskerin/valsartan as effective and safe as either drug in monotherapy for treating hypertension?

A. M. Tato, F. García López

Nefrologia (English Version). 2008;28 Supl 2:10-1

Does nocturnal BP better predict the cardiovascular risk than diurnal BP?

M. López Jiménez, L. Vigil

Nefrologia (English Version). 2008;28 Supl 2:12-3

Has the prevalence of chronic renal disease increased in recent years?

F. García López, V. Barrio

Nefrologia (English Version). 2008;28 Supl 2:14-5

Are optimal doses of benazepril and losartan to reduce proteinuria more nephroprotective than conventional doses in non-diabetic proteinuric nephropathies?

G. Fernández Juárez, V. Barrio

Nefrologia (English Version). 2008;28 Supl 2:16-7

Is a very low protein diet effective in delaying starting on dialysis in the elderly?

F. García López

Nefrologia (English Version). 2008;28 Supl 2:18-9

Does treatment with loop diuretics in acute renal failure reduce mortality or does it decrease the need for dialysis?

V. Barrio, F. García López

Nefrologia (English Version). 2008;28 Supl 2:20-1

Is therapy with intermittent hemodialysis better than using continuous techniques in acute renal failure in adult patients?

V. Barrio, C. Quereda

Nefrologia (English Version). 2008;28 Supl 2:22-3

Is oral antibiotic therapy equally effective than parenteral therapy in the first acute pyelonephritis episode in children?

M. Espino, V. Barrio

Nefrologia (English Version). 2008;28 Supl 2:24-5

Does intra-dialysis parenteral nutrition improve survival in hemodialysis?

V. Barrio, A. M. Tato

Nefrologia (English Version). 2008;28 Supl 2:26-7

Is CERA therapy every 2-4 weeks worse than usual EPO therapy 1-3 times per week?

R. Saracho Rotaeche

Nefrologia (English Version). 2008;28 Supl 2:28-9

Do biocompatible solutions better protect residual renal function than conventional solutions used in peritoneal dialysis?

G. del Peso, M. A. Bajo

Nefrologia (English Version). 2008;28 Supl 2:30-1

Is the automated peritoneal dialysis technique better than ambulatory continuous peritoneal dialysis for patients starting on peritoneal dialysis?

J. Portolés, M. A. Bajo

Nefrologia (English Version). 2008;28 Supl 2:32-3

What are the effectiveness and safety of post-renal transplantation pharmacological therapy for bone disease?

P. Delgado, D. Hernández

Nefrologia (English Version). 2008;28 Supl 2:34-5

Is long-term immunosuppression without anti-calcineurinic agents safe in renal transplantation?

J. M. Díaz

Nefrologia (English Version). 2008;28 Supl 2:36-7

Does conversion from Cyclosporin to Azathioprine done at 12 months post-renal transplantation in stable patients have

J. J. Amenábar, F. García López

Nefrologia (English Version). 2008;28 Supl 2:38-9

Is it possible to sustain adequate immunosuppressive efficacy minimizing the nephrotoxicity with a regimen including low doses of calcineurin inhibitors or sirolimus?

S. Jiménez, J. Zamora, A. Muriel, J. Pascual

Nefrologia (English Version). 2008;28 Supl 2:40-1

Evidence-based nephrology: The Cochrane Renal Review Group

Julio Pascual, N. WILLIS

Nefrologia (English Version). 2008;28 Supl 2:46-50

Idiomas

Nefrología (English Edition)